Nasdaq · CIK 0001896212
CDT CONDUIT PHARMACEUTICALS INC.
Insider trading from SEC Form 4. Last filing 40 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at CONDUIT PHARMACEUTICALS INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Andrew Regan Chief Executive Officer | JOther Common Stockindirect: By Corvus Capital Ltd. | +5,436,830 | - | - | 5,693,223 | 40 d ago |
| Aug 28, 2026 | Andrew Regan Chief Executive Officer | SOpen-market sale Common Stockindirect: By Corvus Capital Ltd. | -290 | - | - | 5,692,933 | 40 d ago |
| Jul 30, 2026 | Andrew Regan Chief Executive Officer | JOther Pre-Funded Warrantsderivativeindirect: By Corvus Capital Ltd. | +5,436,830 | $0.00 | $544 | 5,436,830 | 40 d ago |
| Aug 28, 2026 | Andrew Regan Chief Executive Officer | XIn-the-money exercise Pre-Funded Warrantsderivativeindirect: By Corvus Capital Ltd. | -5,436,830 | $0.00 | $544 | 0 | 40 d ago |
| Jun 3, 2025 | Andrew Regan Chief Executive Officer | AGrant or award Common Stockindirect: See Footnote | +154,799 | $3.23 | $500k | 154,799 | Jun 13, 2025 |
| Apr 16, 2025 | Faith L. Charles director | AGrant or award Common Stock | +115,194 | $0.87 | $100k | 165,238 | Apr 17, 2025 |
| Mar 30, 2025 | Faith L. Charles director | AGrant or award Common Stock | +46,629 | $0.89 | $41k | 50,044 | Apr 1, 2025 |
| Mar 30, 2025 | Chele Chiavacci Farley director | AGrant or award Common Stock | +32,022 | $0.89 | $28k | 35,537 | Apr 1, 2025 |
| Mar 30, 2025 | Simon Jeremy Fry director | AGrant or award Common Stock | +29,354 | $0.89 | $26k | 31,354 | Apr 1, 2025 |
| Mar 30, 2025 | Freda C Lewis-Hall director | AGrant or award Common Stock | +47,612 | $0.89 | $42k | 51,991 | Apr 1, 2025 |
| Dec 18, 2024 | Simon Jeremy Fry director | AGrant or award Stock Option (Right to Buy)derivative | +420,000 | $0.07 | $30k | 420,000 | Dec 20, 2024 |
| Dec 18, 2024 | Freda C Lewis-Hall director | AGrant or award Stock Option (Right to Buy)derivative | +420,000 | $0.07 | $30k | 420,000 | Dec 20, 2024 |
| Dec 18, 2024 | Chele Chiavacci Farley director | AGrant or award Stock Option (Right to Buy)derivative | +420,000 | $0.07 | $30k | 420,000 | Dec 20, 2024 |
| Dec 18, 2024 | Faith L. Charles director | AGrant or award Stock Option (Right to Buy)derivative | +420,000 | $0.07 | $30k | 420,000 | Dec 20, 2024 |
| Nov 18, 2024 | James Bligh Interim CFO | AGrant or award Stock Option (Right to Buy)derivative | +1,890,000 | $0.09 | $174k | 1,890,000 | Nov 20, 2024 |
| Nov 18, 2024 | Faith L. Charles director | AGrant or award Common Stock | +75,000 | - | - | 75,000 | Nov 20, 2024 |
| Nov 18, 2024 | Chele Chiavacci Farley director | AGrant or award Common Stock | +299,238 | $0.09 | $27k | 351,510 | Nov 20, 2024 |
| Nov 18, 2024 | Freda C Lewis-Hall director | AGrant or award Common Stock | +437,976 | $0.09 | $40k | 437,976 | Nov 20, 2024 |
| Nov 18, 2024 | David Tapolczay Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +840,000 | $0.09 | $77k | 840,000 | Nov 20, 2024 |
| Nov 18, 2024 | Faith L. Charles director | AGrant or award Common Stock | +266,594 | $0.09 | $24k | 341,594 | Nov 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- James BlighInterim CFO
- Faith L. Charlesdirector
- Chele Chiavacci Farleydirector
- Simon Jeremy Frydirector
- Freda C Lewis-Halldirector
- Andrew ReganChief Executive Officer
- David TapolczayChief Executive Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.